Features of genetically engineered mouse models of CLL
| Mouse model . | Disease penetrance . | Time of appearance of circulating leukemic cells . | Age of death . | IG gene rearrangements . |
|---|---|---|---|---|
| mir-15a/16-1−/− and mir-15a/16-1floxed CD19-Cre | ∼20% CLL | 12-18 mo | 15-18 mo | Unmutated and stereotypic IGHV genes |
| ∼8% MBL | ||||
| ∼2% CD5– NHL | ||||
| 14qC3-MDR−/− and MDRfloxedCD19-Cre | ∼22% CLL | 6-18 mo | 12-18 mo | Unmutated and stereotypic IGHV genes |
| ∼12% MBL | ||||
| ∼6% CD5– NHL | ||||
| 14qC3-CDRfloxedCD19-Cre | ∼50% CLL | 6-18 mo | 12-18 mo | Unmutated and stereotypic IGHV genes |
| ∼3% MBL | ||||
| Eμ-TCL1 tg | 100% CLL | 6 mo | 12-18 mo | Unmutated IGHV genes, stereotypic IGHV and IGLV genes |
| APRIL tg | 40% CLL | Not analyzed | 12 to >15 mo | Not analyzed |
| BCL2 × traf2dn tg | 80% CLL | 9-15 mo | >80% dead at 14 mo | Clonal IGHV rearrangements |
| ROR1 tg | 5% CLL | >15 mo | >15 mo | Clonal IGHV rearrangements |
| Eμ-mir-29 tg | 20% CLL | 12-24 mo | 24-26 mo | Clonal IGHV rearrangements |
| Vh11 × irf4−/− | 100% CLL (preceded by MBL in >40% cases) | 5-10 mo | >9 mo | Clonal IGHV rearrangements (determined by FACS) |
| IgH.TEμ | 100% CLL | <5 mo | Killed at 2-10 mo | Unmutated IGHV genes (preferentially Vh11) and some highly mutated |
| Mouse model . | Disease penetrance . | Time of appearance of circulating leukemic cells . | Age of death . | IG gene rearrangements . |
|---|---|---|---|---|
| mir-15a/16-1−/− and mir-15a/16-1floxed CD19-Cre | ∼20% CLL | 12-18 mo | 15-18 mo | Unmutated and stereotypic IGHV genes |
| ∼8% MBL | ||||
| ∼2% CD5– NHL | ||||
| 14qC3-MDR−/− and MDRfloxedCD19-Cre | ∼22% CLL | 6-18 mo | 12-18 mo | Unmutated and stereotypic IGHV genes |
| ∼12% MBL | ||||
| ∼6% CD5– NHL | ||||
| 14qC3-CDRfloxedCD19-Cre | ∼50% CLL | 6-18 mo | 12-18 mo | Unmutated and stereotypic IGHV genes |
| ∼3% MBL | ||||
| Eμ-TCL1 tg | 100% CLL | 6 mo | 12-18 mo | Unmutated IGHV genes, stereotypic IGHV and IGLV genes |
| APRIL tg | 40% CLL | Not analyzed | 12 to >15 mo | Not analyzed |
| BCL2 × traf2dn tg | 80% CLL | 9-15 mo | >80% dead at 14 mo | Clonal IGHV rearrangements |
| ROR1 tg | 5% CLL | >15 mo | >15 mo | Clonal IGHV rearrangements |
| Eμ-mir-29 tg | 20% CLL | 12-24 mo | 24-26 mo | Clonal IGHV rearrangements |
| Vh11 × irf4−/− | 100% CLL (preceded by MBL in >40% cases) | 5-10 mo | >9 mo | Clonal IGHV rearrangements (determined by FACS) |
| IgH.TEμ | 100% CLL | <5 mo | Killed at 2-10 mo | Unmutated IGHV genes (preferentially Vh11) and some highly mutated |